Lung D702GC00001 Artemide-Lung04

A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab Monotherapy for the First-line Treatment of Patients with PD-L1-high Metastatic Non-small Cell Lung Cancer

Sponsor: National Cancer Institute (NCI)

Interested in this trial? Email [email protected].